Mouse study links CBD’s anxiety-like effects to LHb α3 glycine receptors

Cannabidiol alleviates anxiety-like behaviors via α3-containing glycine receptors in the lateral habenula.

Neuropharmacology • • Highly Relevant
🤖

AI Summary

This study asked whether cannabidiol (CBD) reduces anxiety-like behavior through glycine receptors in the lateral habenula (LHb). Using behavioral tests and brain-cell recordings in mice, the researchers found that giving CBD either systemically or directly into the LHb alleviated anxiety-like behaviors. Blocking LHb glycine receptors caused anxiety-like behaviors, and CBD did not reverse those behaviors after the receptors had been blocked.

Further experiments identified α3-containing glycine receptors as necessary for the observed effects: deleting this receptor subtype in the LHb produced anxiety-like behaviors and eliminated CBD’s behavioral and neuronal effects, while deleting the α1 subtype did not produce the same result. CBD also reduced LHb neuron excitability when α3-containing receptors were present. These mouse findings identify a possible mechanism, but the abstract does not establish that CBD treats anxiety disorders in people; it reports no human results, and this abstract-based summary cannot assess the study’s full methods or limitations.

💡 Key Findings

1
In mice, systemic and LHb-administered CBD alleviated anxiety-like behaviors; blocking LHb glycine receptors induced such behaviors, which CBD did not reverse after blockade.
High
80%
2
Deleting LHb α3-containing glycine receptors produced anxiety-like behaviors and abolished CBD’s reported anxiolytic effect; deleting α1-containing receptors did not produce the same behavioral result.
High
80%
3
CBD raised the action-potential threshold and reduced LHb neuron firing, and these effects were absent in mice lacking LHb α3-containing glycine receptors.
High
80%

📄 Original Abstract

Cannabidiol (CBD) exerts potent anxiolytic effects, yet the brain nuclei and molecular targets mediating these effects remain poorly defined. Here, using behavioral and electrophysiological approaches, we identify glycine receptors (GlyRs) in the lateral habenula (LHb) as a key mediator of CBD's anxiolytic action. Pharmacological blockade of LHb GlyRs by intra-LHb strychnine induces robust anxiety-like behaviors, whereas both systemic and intra-LHb CBD administration alleviate them. However, CBD failed to reverse the anxiety-like behaviors induced by prior intra-LHb strychnine. Consistent with this, whole-cell recordings reveal strychnine-sensitive tonic currents in LHb neurons, implicating extrasynaptic GlyRs. To define the responsible subtype, we generated conditional knockouts and found that deletion of α3-containing GlyRs (GlyRα3 cKO), but not α1-containing GlyRs (GlyRα1 cKO), in the LHb produces robust anxiety-like behaviors. Notably, CBD exerts no anxiolytic effect in GlyRα3 cKO mice, establishing GlyRα3 as the subtype required for CBD's action. Furthermore, CBD elevates the action potential threshold and reduces the firing rate of LHb neurons, effects abolished in GlyRα3 cKO mice, thereby linking GlyRα3 activation to reduced LHb excitability. Collectively, these findings identify LHb GlyRα3 as a novel molecular target underlying CBD's anxiolytic effects and support CBD as a promising therapeutic for anxiety disorders.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.